Anticipated Earnings Release: Co-Diagnostics, Inc. (NASDAQ:CODX) is set to announce its Q4 and full-year 2025 financial results on March 31, 2026, with an expected EPS of -$3.60.Financial Metrics Overview: CODX showcases a mixed financial outlook with a price-to-sales ratio of 4.44 and an enterprise value to operating cash flow ratio of 0.25, indicating positive market perception and efficient cash flow conversion, respectively.Challenges Ahead: Despite strong liquidity and a conservative capital structure, ...

Co-Diagnostics Ships Diagnostic Materials to India for Initiation of Tuberculosis Clinical Studies Following Recently Issued Guidance from the World Health Organization Accessibility StatementSkip Navigation Despite achieving a 21% reduction in TB incidence since 2015, India continues to account for approximately 25% of global cases according to the 2025 Global tuberculosis report. Mr. Egan continued, "The Co-Dx PCR MTB test has continued to generate encouraging third-party preclinical results, supporting f ...

Co-Diagnostics Begins Shipments To Support India TB StudiesThese materials are necessary to begin clinical performance studies of the TB test on the PCR platform, as the company completes final steps toward initiating those studies in the near term.Last week, Co-Diagnostics signed an agreement for CoSara Diagnostics Pvt. Ltd, to expand its commercial and distribution territory across South Asia to include Bangladesh, Pakistan, Nepal, and Sri Lanka.WHO Guidance Aligns With Company's TB Testing ApproachThe co ...

Co-Diagnostics Signs Agreement to Significantly Expand Commercial and Distribution Territory Across South Asia Accessibility StatementSkip Navigation Expansion into Bangladesh, Pakistan, Nepal, and Sri Lanka increases TAM in region to $13 billion and supports commercialization strategy for the PCR Pro® and SARAGENE® product line SALT LAKE CITY, March 20, 2026 /PRNewswire/ -- Co-Diagnostics, Inc.(Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for th ...

CoSara is the Indian joint venture between Co-Dx and Ambalal Sarabhai Enterprises Limited.Co-Diagnostics, most recently, regained NASDAQ listing compliance.Territory Expansion Unlocks $13 Billion Market OpportunityThe expansion significantly increases CoSara's addressable market across South Asia, bringing the total regional opportunity to an estimated $13 billion based on internal analyses and third-party market data.It also supports CoSara's plans to commercialize the CoSara PCR Pro point-of-care instrume ...

Co-Diagnostics Announces Fourth Quarter and Full Year 2025 Earnings Release Date and Webcast Accessibility StatementSkip NavigationSALT LAKE CITY, March 17, 2026 /PRNewswire/ -- Co-Diagnostics, Inc.(Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced it will release its fourth quarter and full year 2025 financial results on Tuesday, March 31, 2026, after the market close. The Company wil ...

Core Insights - Co-Diagnostics, Inc. has regained compliance with NASDAQ listing requirements and resumed trading on March 11, 2026, enhancing its capital markets position [1] - The company is actively expanding its global presence and intellectual property, participating in Medical Korea 2026 to showcase its Co-Dx PCR point-of-care platform [2] - A new patent granted by the Japan Patent Office supports the Co-Dx PCR Pro® instrument and strengthens the company's international IP protection [3] - As of March 13, 2026, CODX stock closed at $2.80, with a market capitalization of approximately $5.87 million [4] - Co-Diagnostics is positioned as an emerging player in molecular diagnostics, focusing on clinical studies and global expansion [5] Group 1 - Co-Diagnostics has regained compliance with NASDAQ listing requirements and resumed trading on March 11, 2026, confirming compliance with the $1.00 minimum bid price rule [1] - The company will participate in Medical Korea 2026 in Seoul, South Korea, from March 19-22, 2026, showcasing its innovative diagnostic solutions [2] - The Japan Patent Office granted a patent that supports the Co-Dx PCR Pro® instrument, enhancing the company's international IP protection [3] Group 2 - CODX stock closed at $2.80 on March 13, 2026, reflecting a 3.75% increase, with a trading volume of 1,105,301 shares [4] - The company is focusing on clinical studies, regulatory pathways, and global expansion for its point-of-care technologies [5]

Core Insights - Co-Diagnostics, Inc. will participate in Medical Korea 2026, a significant healthcare conference in Seoul, South Korea, from March 19-22, 2026, alongside various Utah legislative and industry delegates [1][3] Group 1: Event Participation - Co-Diagnostics will engage in a healthcare business roundtable and present its upcoming Co-Dx PCR point-of-care platform during the conference [2] - The conference is expected to attract over 6,000 participants from more than 50 countries, featuring B2B introductions, presentations, and special sessions [2] Group 2: Strategic Importance - South Korea is identified as a priority partner for Utah, with efforts to strengthen trade and investment corridors between the two regions [3] - The World Trade Center Utah is organizing the delegation to enhance Utah's presence and partnerships within South Korea's healthcare ecosystem [3] Group 3: Conference Overview - Medical Korea 2026 serves as a premier platform for global healthcare collaborations, bringing together international healthcare leaders, government officials, and industry innovators [4] - The event aims to highlight emerging medical technologies and foster cross-border partnerships in healthcare and life sciences [4] Group 4: Company Overview - Co-Diagnostics specializes in molecular diagnostics, developing and marketing advanced diagnostic technologies that utilize nucleic acid detection and analysis [6] - The Co-Dx PCR platform, which includes various products, is currently under regulatory review and not yet available for sale [5][6]

Core Viewpoint - Co-Diagnostics, Inc. will participate in the World Health Expo Labs Dubai to showcase its molecular diagnostic technologies and engage with regional stakeholders, following the establishment of a joint venture to enhance its market presence in the Middle East and North Africa [1][3]. Company Participation - The exhibition will take place from February 10–13, 2026, at the Dubai World Trade Centre, where Co-Diagnostics will have a booth (S17.C79) [3]. - The participation aligns with the company's strategy to expand access to high-quality molecular diagnostics in the region [3]. Joint Venture - Co-Diagnostics has formed a joint venture named CoMira Diagnostics with Arabian Eagle Manufacturing in Saudi Arabia, aimed at localizing the manufacturing and distribution of its technologies across Saudi Arabia and 18 additional countries in the MENA region [3]. Product Information - The Co-Dx PCR platform, which includes various applications and tests, is currently undergoing clinical studies in the United States and is subject to regulatory review [5][6]. - The company's technologies focus on the detection and analysis of nucleic acid molecules (DNA or RNA) for various diagnostic applications [6].

Core Viewpoint - Co-Diagnostics, Inc. and CoSara Diagnostics have achieved ISO 13485:2016 certification for their quality management system, which is essential for regulatory clearance of their new PCR platform and other medical devices [1][2][4] Group 1: Certification and Compliance - CoSara has successfully completed audits of its quality management system, leading to the ISO 13485:2016 certification for its manufacturing facility in Vadodara, India [1][2] - The certification is a significant milestone that validates the efforts of CoSara's Quality team in maintaining high international standards [2] - ISO 13485 certification ensures compliance with best practices in medical device manufacturing, facilitating market access and enhancing stakeholder trust [2] Group 2: Regulatory and Market Implications - The certification is crucial for demonstrating compliance to regulatory bodies in India and internationally, aiding in the clearance of the upcoming PCR platform and other medical devices [2][4] - The Co-Dx PCR platform, which includes various products, is currently under review by the FDA and is not yet available for sale [5] - Manufacturing under the 'Make in India' initiative will provide cost advantages compared to importing products into India [4] Group 3: Development and Future Plans - Recent visits by Co-Dx staff to India were aimed at finalizing software for tuberculosis and HPV tests, as well as supporting manufacturing lines for commercialization [3] - The completion of audits aligns with ongoing efforts to prepare for clinical performance studies and regulatory submissions [3][4]